Evaxion Biotech A/SEvaxion Biotech A/SEvaxion Biotech A/S

Evaxion Biotech A/S

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪21.07 M‬USD
−8.24USD
‪−22.16 M‬USD
‪73.11 K‬USD
Beta (1Y)
0.88

About Evaxion Biotech A/S

CEO
Christian Kanstrup
Headquarters
Hoersholm
Employees (FY)
49
Founded
2008
FIGI
BBG00YTSS733
Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen Møller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.